+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID07581821

Phase 2 Study of Sintilimab With Anlotinib and Taxane Chemotherapy for Adults 18-65 With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Tried Previous Treatments

Led by Ming-Yuan Chen · Updated on 2026-05-12

33

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a combination treatment involving sintilimab, anlotinib, and taxane-based chemotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma NPC who have not been cured by local treatments and have failed previous first-line platinum chemotherapy or immunotherapy. This Phase 2 study focuses on patients with this condition who need new treatment options. The trial is designed to assess how well this triple combination works and how safe it is for participants. The treatment regimen includes sintilimab given intravenously at 200mg on day 1 every three weeks, anlotinib taken orally at 12mg daily from day 1 to day 14 every three weeks, and a taxane chemotherapy drug selected from docetaxel, paclitaxel, or nab-paclitaxel administered intravenously once every three weeks for up to six cycles. After chemotherapy, patients continue receiving sintilimab and anlotinib every three weeks for up to two years or until disease progression or other study endpoints occur. Participants will attend regular visits where the research team will conduct imaging exams and other assessments to monitor treatment response and safety. The primary outcome is the objective response rate measured over an average of two years, with additional evaluations including disease control, duration of response, progression-free survival, and overall survival. The study continues until disease progression, intolerable side effects, withdrawal, new therapy initiation, loss of follow-up, death, or study completion.

CONDITIONS

Brief Title

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Research Team

M

Ming-Yuan Chen, MD, PhD

J

Jijin Yao, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here